Q2 2019 EPS Estimates for Aptevo Therapeutics Inc Decreased by Analyst (NASDAQ:APVO)

Aptevo Therapeutics Inc (NASDAQ:APVO) – Equities researchers at Piper Jaffray Companies lowered their Q2 2019 EPS estimates for shares of Aptevo Therapeutics in a report issued on Tuesday, June 25th, Zacks Investment Research reports. Piper Jaffray Companies analyst E. Tenthoff now expects that the biotechnology company will earn ($0.28) per share for the quarter, down from their prior estimate of ($0.27). Piper Jaffray Companies has a “Overweight” rating and a $4.50 price objective on the stock. Piper Jaffray Companies also issued estimates for Aptevo Therapeutics’ Q4 2019 earnings at ($0.28) EPS, FY2019 earnings at ($1.22) EPS, Q1 2020 earnings at ($0.28) EPS and FY2020 earnings at ($1.19) EPS.

Aptevo Therapeutics (NASDAQ:APVO) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.44). The firm had revenue of $7.02 million for the quarter, compared to analysts’ expectations of $6.30 million. Aptevo Therapeutics had a negative net margin of 199.24% and a negative return on equity of 122.33%.

APVO has been the topic of several other reports. ValuEngine downgraded shares of Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Roth Capital reiterated a “buy” rating on shares of Resverlogix in a report on Thursday, May 23rd. Finally, Zacks Investment Research downgraded shares of GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a report on Thursday, July 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $7.88.

Shares of NASDAQ APVO traded down $0.01 during mid-day trading on Thursday, hitting $0.87. 848,028 shares of the company’s stock traded hands, compared to its average volume of 539,557. The company has a market capitalization of $39.12 million, a P/E ratio of -0.36 and a beta of 2.39. Aptevo Therapeutics has a 1 year low of $0.67 and a 1 year high of $5.80. The business has a 50-day moving average of $0.86. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.15 and a quick ratio of 2.91.

In related news, CEO Marvin L. White purchased 50,000 shares of the firm’s stock in a transaction on Friday, June 14th. The stock was acquired at an average price of $0.88 per share, with a total value of $44,000.00. Following the completion of the acquisition, the chief executive officer now owns 293,603 shares in the company, valued at approximately $258,370.64. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have purchased 241,365 shares of company stock valued at $199,482 in the last three months. 11.74% of the stock is currently owned by corporate insiders.

Large investors have recently bought and sold shares of the company. Acadian Asset Management LLC lifted its stake in shares of Aptevo Therapeutics by 4.8% in the fourth quarter. Acadian Asset Management LLC now owns 462,824 shares of the biotechnology company’s stock worth $587,000 after buying an additional 21,059 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Aptevo Therapeutics by 1.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,442,049 shares of the biotechnology company’s stock valued at $1,831,000 after acquiring an additional 16,482 shares during the period. Clifford Swan Investment Counsel LLC purchased a new stake in shares of Aptevo Therapeutics in the 4th quarter valued at approximately $35,000. Deutsche Bank AG raised its stake in shares of Aptevo Therapeutics by 251.7% in the 4th quarter. Deutsche Bank AG now owns 330,200 shares of the biotechnology company’s stock valued at $419,000 after acquiring an additional 236,300 shares during the period. Finally, Marshall Wace LLP acquired a new position in shares of Aptevo Therapeutics in the first quarter valued at approximately $33,000. 36.37% of the stock is currently owned by hedge funds and other institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.

Featured Story: What does relative strength index mean?

Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.